Breast cancer: decline in deaths explained by use of screening and adjuvant therapies
Early detection through screening mammography and improved adjuvant treatment have contributed almost equally to the substantial decrease in breast cancer death rates over the past 10 to 15 years, researchers conclude in an unprecedented effort to parse out the factors that have led to the decline.
The study is published in the New England Journal of Medicine.
Researchers sought to end the longstanding controversy of whether screening mammography, better treatment or a combination of the two is responsible for improved breast cancer survival. The seven teams consisting of 43 investigators designed their own statistical models to determine the contribution of each method. These independent models used the same sources of data, some of which had not been mined before, but their approaches and assumptions differed.
The teams reached somewhat different conclusions, but were closest to each other in estimating how much the adjuvant therapies Tamoxifen and chemotherapy reduced mortality in patients ( 12 percent to 21 percent, with a median of 19 percent ). The range for screening mammography, however, was 7 percent to 23 percent ( with a median of 15 percent ), reflecting the greater uncertainty associated with estimating the benefit of screening.
Still, according to the models, the combination of screening and adjuvant therapy together reduced the breast cancer death rate by an estimated 25 percent to 38 percent, with a median of 30 percent - which explains the drop in breast cancer mortality from 1975 to 2000, says the study's lead author, Donald Berry, at M. D. Anderson Cancer Center.
" While we didn't agree with each other as to the percentages of benefit, all seven groups concluded that the decline in the rate of death from breast cancer is a combination of screening and therapy and not restricted to one or the other," he says. " Screening would have no benefit if not followed by treatment, including surgery, and treatment has the potential to be more effective if cancer is detected at earlier stages by screening."
Berry stresses that the differences in conclusions reflect uncertainties in the interpretation of available information and differing modeling approaches, rather than contradictions among the models. " These are seven top modeling groups applying their efforts to the best data that we have available in this country," he says.
He adds that the survival benefits offered by screening and adjuvant therapy both may be lower than researchers had expected. " Some people think the benefit of screening is huge, and others say that the reduction in death rates is due primarily to adjuvant therapy, " Berry says. " No one has known for sure, and although we still don't know for sure, this is the best set of analyses that is possible given the available information."
The study was undertaken by the Cancer Intervention and Surveillance Modeling Network ( CISNET ), a consortium of investigators sponsored by the NCI whose purpose is to measure the effect of cancer-control interventions on the incidence of and risk of death from cancer in the general population. The seven breast cancer teams involved in this study are from Dana-Farber Cancer Institute in Boston; Erasmus University Medical Center in Rotterdam, the Netherlands; Georgetown University; M. D. Anderson Cancer Center; Stanford University; the University of Rochester; and the University of Wisconsin-Madison.
Researchers say there is no question that breast cancer death rates have fallen in recent decades, both in the United States and in other countries. In 1975, the rate of death from breast cancer among women 30 to 79 years of age, adjusted for age to the 2000 population, was 48.3 deaths per 100,000 women. By 1990, the rate had increased slightly to 49.7 per 100,000, but then fell to 38.0 per 100,000 by 2000, a decrease of 24 percent from 1990.
The two major changes in breast oncology over that time have been the advent of screening mammography ( which 70 percent of women over age 40 received in 2000 ) and the use of adjuvant therapies - chemotherapy and hormone therapy used in conjunction with primary treatment by surgery and/or radiation. But because each of these factors gained in popularity and use at about the same time, it is not a simple matter to separate out the relative contribution of each to improved survival, Berry says.
To find out, the CISNET groups used data that reflected "real life" use of screening and adjuvant therapy, including some population databases that had not been tapped before for this purpose. Their analysis relied on the incidence of breast cancer as reported by the Surveillance, Epidemiology, and End Results ( SEER ) program and the rate of death from breast cancer as reported by the National Center for Health Statistics ( NCHS ), as well as additional databases concerning uses of screening and treatment and their efficacy in the population.
The models reached somewhat different estimates. Dana-Farber's model found that screening mammography accounted for 65 percent of the reduced breast cancer death rate ( with 35 percent due to use of chemotherapy and Tamoxifen ) while the M. D. Anderson model reached the opposite conclusion - that 65 percent of the mortality benefit is due to adjuvant chemotherapy and 35 percent is due to screening.
Berry has studied mammography and has focused on its downside. He says that the researchers in the study are comfortable with the level of disagreement concerning their point estimates and with the level of uncertainty reflected in their overall conclusions. In his opinion, "the evidence makes clear that the benefit of screening on breast cancer mortality is very likely while the benefit of providing adjuvant therapy is certain." He adds that he continues to feel strongly that women should be informed of the risks of screening as well as the benefits, and says he is "happy to have helped further quantify the latter."
The models now in place can be used to answer a number of questions related to screening and treatment, Berry says. " They provide a way for assessing the benefits of screening and treatment strategies different from the ones that were actually in place over the time period of the study," he says. " For example, our models can address what the effect on mortality would be if all women in particular age groups were to be screened at regular intervals. And it allows for addressing the impact on overall mortality if effective therapies were made available to particular types of patients with breast cancer."
In this way, the models may "help determine what strategies for delivering medical care are best for patients," Berry says. " And that is necessary, since our efforts, taken as a whole, haven't come close to eliminating breast cancer mortality."
Source: University of Texas M. D. Anderson Cancer Center, 2005
As part of an ongoing phase Ib/II study ( NCT02501096 ) in patients with selected solid tumors, Lenvatinib [ Lenvima...
Management of hepatocellular carcinoma with portal vein tumor thrombus: new evidence and perspectives
Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its...
Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after Platinum-containing chemotherapy
The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1...
Abraxane for first-line treatment of patients with non-small cell lung cancer, positive CHMP opinion
The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...
The aim of American Society of Clinical Oncology ( ASCO ) Clinical Practice Guideline is to provide evidence-based recommendations to...
LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with...
Impact of human papillomavirus on distant metastatic failure patterns in squamous cell cancer of the oropharynx in patients treated with chemoradiation
HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic...
Glioblastoma ( GBM ) is the most common primary malignant adult brain tumor and, despite treatment advances in recent years,...
Although anti–CTLA-4 and anti–PD-1 monoclonal antibodies ( mAbs ) may overcome T-cell suppression, T-cell activation depends on the engagement of...
Muscle invasive bladder cancer: transurethral surgery and twice-daily radiation plus Paclitaxel - Cisplatin or Fluorouracil - Cisplatin with selective bladder preservation and adjuvant chemotherapy
Researchers has assessed effectiveness, safety, and tolerability of Paclitaxel or Fluorouracil when added to radiation plus Cisplatin followed by adjuvant...